Engflag

Domak

Quick links to important sections

Domak

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Domak

What is Domak?

Domak is a pharmaceutical medication primarily utilized for its prokinetic properties, which assist in the movement of food through the digestive tract. It belongs to a class of medications known as dopamine antagonists. Unlike some other medications in this category, it is specifically designed to act on receptors located primarily in the peripheral nervous system rather than the central nervous system.

Mechanism of Action

The active component in Domak works by blocking dopamine receptors. In the gastrointestinal system, dopamine can inhibit the smooth muscle contractions necessary for moving contents through the stomach and intestines. By antagonizing these receptors, Domak helps to:

  • Facilitate gastric emptying
  • Increase the tone of the lower esophageal sphincter
  • Coordinate the movement between the stomach and the small intestine

Common Clinical Uses

This medication is typically indicated for the management of symptoms associated with slowed gastrointestinal transit. These symptoms may include a persistent feeling of fullness, bloating, or upper abdominal discomfort. It is also frequently used to manage nausea and vomiting that may arise from various underlying conditions or as a secondary effect of other medical treatments.

Because of its specific design, it focuses on the gastrointestinal triggers of these symptoms, aiming to restore the natural rhythm of the digestive process.

What side effects are possible with Domak?

Possible Side Effects and Safety Information

The safety profile of Domak (Amikacin) is primarily defined by the potential for systemic toxicities inherent to the aminoglycoside class, as documented in official regulatory labels. These effects are classified based on the organ system affected and the frequency of occurrence.

Key Adverse Reaction Categories

Adverse reactions are formally classified by government health authorities, concentrating on three critical areas:

  • Nephrotoxicity (Renal and Urinary Disorders): Effects on kidney function, including elevated creatinine or acute renal failure (Incidence Not Known).
  • Ototoxicity (Ear and Labyrinth Disorders): Damage to the inner ear, which can result in hearing loss (auditory function) or problems with balance (vertigo).
  • Neurotoxicity (Nervous System Disorders): Effects such as paresthesia and the potential for neuromuscular blockade, which can lead to respiratory paralysis (Incidence Not Known).

Frequency and Duration Patterns

  • Common Reactions (1% to 10%): The official label includes Nephrotoxicity and Hearing loss within this frequency band.
  • Serious Adverse Reactions: The regulatory framework highlights severe, though less frequent, risks, including Irreversible bilateral deafness and Acute renal failure. The risk of nephrotoxicity is cumulative, and ototoxicity may manifest after treatment has been concluded, known as a latency effect.

Population-Specific Safety Notes

The risk of both nephrotoxicity and ototoxicity is formally noted as being greater in older adults and in patients with pre-existing renal impairment, requiring specific consideration. Furthermore, the official label notes that Amikacin can cause fetal harm and is contraindicated in cases of Myasthenia Gravis due to the risk of severe neuromuscular blockade.

Overdose and Emergency Response

Overdose and When to Seek Help

Domak (referring to the regulatory profile of dronedarone) is associated with serious documented risks that require immediate medical attention. The most severe are hepatic injury and an increased risk of death in specific patient populations.

Immediate medical help is required if you experience symptoms suggesting liver toxicity, which include: yellowing of the skin or eyes (jaundice), dark urine, unusual fatigue, loss of appetite, nausea, vomiting, and pain in the upper right side of the abdomen. Severe cases of hepatocellular injury, including acute liver failure requiring transplantation, have been reported in the post-marketing setting.

In the event of a suspected overdosage, the treatment approach is strictly supportive and based on the symptoms presented. Official regulatory guidance emphasizes monitoring the patient's cardiac rhythm and blood pressure. There is no specific antidote available, and it is unknown whether the substance can be removed by standard dialysis procedures.

Population-Specific Risk: The drug is specifically contraindicated for patients with certain advanced heart conditions, such as symptomatic decompensated heart failure or permanent atrial fibrillation, due to an increased risk of death, stroke, and hospitalization for heart failure in these groups. Immediate discontinuation and reporting of signs of hepatic injury or heart failure worsening is a critical regulatory requirement for patient safety.

Therapeutic Uses of Domak

What Domak Treats: Main Uses and Benefits

Domak (Amikacin) is commonly used to help manage serious bacterial infections in situations where standard treatments may be ineffective due to pathogen resistance. The medication is utilized for conditions including Multidrug-resistant Mycobacterium tuberculosis and Sepsis (without septic shock). It is relevant in contexts involving heightened systemic burden caused by often hospital-acquired bacteria.

Managing Symptoms of Life-Threatening Sepsis and Critical Infections

Domak plays a role in managing urgent, high-risk conditions such as sepsis and septicemia, and is commonly used in clinical settings that involve acute or unstable symptom patterns. Its use helps address symptom clusters that may become intense or disruptive, including systemic imbalance and organ-specific functional stress. The medication assists with stabilizing the physiological strain caused by overwhelming infection.

Addressing Symptoms Driven by Multidrug-Resistant (MDR) Pathogens

Domak is highly relevant in clinical situations where infections are associated with multidrug-resistant Gram-negative bacteria, such as strains of Pseudomonas or Acinetobacter, which cause conditions marked by increased physiological stress. It is applied in scenarios where additional management of discomfort is required because the infection has resisted first-line treatments. This contributes to easing the overall symptom load in conditions where symptoms are linked to an active, persistent infection.

Quick Fact: Relevant for Systemic Discomfort
Domak is relevant when symptoms relate to systemic imbalance associated with resistant pathogens, contributing to improved comfort when symptoms may intensify temporarily.

Eligibility and Restrictions for Use

Who can and cannot use Domak?

Domak (Amikacin) eligibility is strictly defined by government regulatory documents, focusing on minimizing risks associated with the drug's potential for organ toxicity and neuromuscular effects. Use is permitted for general adult and pediatric populations who do not meet non-eligible criteria.

Absolute Contraindications (Must Not Use)

The medicine is formally contraindicated and must not be used by patients with a known hypersensitivity or allergy to Amikacin or any other aminoglycoside antibiotic due to the demonstrated risk of cross-sensitivity. Use is also prohibited in individuals diagnosed with Myasthenia Gravis due to the documented risk of severe neuromuscular blockade.

Restrictions and Conditional Eligibility

Population / Condition Regulatory Eligibility Status
Impaired Renal Function Use restricted. Requires extreme caution and mandatory monitoring of renal function due to the high risk of nephrotoxicity.
Auditory / Vestibular Status Use restricted. Individuals with pre-existing hearing loss or symptoms like tinnitus are at heightened risk of permanent irreversible ototoxicity.
Pregnancy Contraindicated / Not Recommended. Official labeling includes a warning regarding the risk of causing total, irreversible congenital deafness in the fetus.
Neonates / Older Adults Use with Caution. Neonates require specialized monitoring due to undeveloped renal function, while use in older adults requires vigilance due to age-related decline in kidney function.

What should I know about interactions with other medicines?

The official regulatory documentation for Domak (Amikacin) defines specific interaction constraints based on pharmacodynamic effects and physical compatibility, as the drug is primarily cleared by the kidneys and is not significantly metabolized by the CYP450 system.

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Potent Diuretics, Other Ototoxic or Nephrotoxic Products, Neuromuscular Blocking Agents, Beta-lactam Antibiotics.
Specific interacting medicines (select examples) Furosemide, Ethacrynic Acid, Cisplatin, Vancomycin, Succinylcholine, Indomethacin (in neonates).
Mechanistic basis of interactions Pharmacodynamic Synergism (additive risk of toxicity; potentiation of neuromuscular effects); In Vitro Chemical Incompatibility (inactivation); Reduced Renal Clearance (leading to increased exposure).

Official Interaction Statements

  • Co-administration with potent diuretics (e.g., Furosemide) or other ototoxic/nephrotoxic medicinal products (e.g., Vancomycin, Cisplatin) is cautioned or should be avoided due to the officially documented risk of additive organ toxicity [FDA Prescribing Information].
  • Domak increases the effects of neuromuscular blocking agents (e.g., Succinylcholine) via pharmacodynamic synergism, which may result in prolonged muscular paralysis [HPRA/EMA SmPC].
  • Beta-lactam antibiotics must not be physically mixed with Domak in the same IV solution due to chemical and physical incompatibility, which can cause inactivation and loss of Domak’s potency [WHO-PQ SmPC].
  • In Elderly Patients and those with Impaired Renal Function, the risk of severe toxic interactions is heightened, which is a population-specific interaction note found in the regulatory labeling.

This structure highlights constraints on combining agents with similar toxicity profiles and mandatory procedural rules for intravenous handling, as defined by regulatory authorities.

Mechanism of Action

The mechanism of Amikacin involves a molecular cascade focused on disrupting translation within susceptible bacteria, leading to cell death.

Targeted Ribosomal Paralysis

Amikacin functions as an irreversible inhibitor of protein synthesis by binding specifically to the 30S ribosomal subunit of the target pathogen. This molecular lock-on forces the ribosome to misread the genetic code (mRNA), leading to the construction of nonfunctional, erroneous proteins. This disruption prevents the synthesis of essential structural and enzymatic bacterial proteins.

Self-Potentiating Bactericidal Cascade

These misfolded proteins integrate improperly into the bacterial cell membrane, causing structural alteration and increased permeability. This structural failure allows a dramatic, self-potentiating influx of Amikacin, rapidly escalating the drug's intracellular concentration. This accelerated accumulation and target disruption results in a concentration-dependent bactericidal effect, and a mechanism-dependent Post-Antibiotic Effect (PAE) where suppression of bacterial regrowth is sustained.

Mechanistic Constraints

This mechanism is constrained by bacterial resistance, primarily the production of Aminoglycoside-Modifying Enzymes (AMEs) that chemically inactivate the molecule. Furthermore, the drug's essential uptake is reliant on an energy-dependent transport system that is significantly impaired in anaerobic (low-oxygen) or acidic environments, limiting the full expression of the mechanism's action in certain biological contexts.

Dosage and Administration Information

Domak (Amikacin) administration is governed by precise, standardized protocols that specify the route, dose, and duration of use. It is primarily administered via the parenteral route, which includes Intramuscular (IM) injection or Intravenous (IV) infusion. A specialized Liposomal Inhalation Suspension form is also available for targeted use in specific, chronic lung infections.

The standardized adult dosing is typically based on 15 mg/kg body weight per day. This may be administered either as a single dose once daily (q24h) or divided into two equal doses of 7.5 mg/kg every 12 hours (q12h). The total daily dose is generally constrained, not to exceed 1.5 g. The injectable solution must be diluted with compatible fluids, such as 0.9% Sodium Chloride, and infused over a controlled time, usually 30 to 60 minutes in adults. The medicine must also be administered separately from certain other drugs to avoid physical incompatibility.

The treatment course is defined as short-term, typically restricted to 7 to 10 days. A critical procedural constraint is the requirement for dose adjustment in patients with renal impairment or in older adults. Dosage must be explicitly modified based on the patient’s assessed renal function (creatinine clearance) to ensure proper clearance and adherence to established guidelines.

Recent Clinical Evidence

Research evidence / Overview of Studies for Domak (Amikacin)

This overview focuses exclusively on the official research evidence that describes the clinical evaluation of Domak, including the types of studies conducted, the outcomes they monitored, and the areas where research remains limited, without offering any clinical advice or recommendations.

Evidence for Use in Serious Systemic Infections

Research related to the injectable form of Domak against serious Gram-negative bacterial infections is founded upon decades of historical clinical experience and several older, controlled trials. Studies have primarily been observational and focus on analyzing how the medicine is processed by the body (known as pharmacokinetics). Research describes its application against Gram-negative bacteria in settings like sepsis. Researchers monitored two main outcomes: bacteriological success (the measured clearance of the target organism) and the patient's clinical response over the short-term treatment period.

Evidence for Use in Multidrug-Resistant Tuberculosis (MDR-TB)

The research supporting the use of injectable Domak as a component in combination regimens for MDR-TB is drawn largely from global cohort studies and aggregate patient data analyses compiled by major health organizations. Studies were designed to monitor long-term outcomes for patients with forms of tuberculosis resistant to initial therapies. The main outcome studied was Sputum Culture Conversion, which is a key measurement of sustained pathogen elimination over many months. Findings describe patterns observed when Domak was included in these specific drug combinations.

Evidence for Use in Refractory MAC Lung Disease (Inhalation)

The specialized liposomal inhalation suspension was evaluated in controlled Phase 3 Trials involving adults whose Mycobacterium avium complex (MAC) lung disease had not responded to at least six months of conventional multi-drug therapy. Studies monitored a microbiological endpoint (Sputum Culture Conversion) and functional measures (such as the 6-Minute Walk Distance). The data gathered for the functional outcomes varied across the observed population in the pivotal trial. The regulatory approval for the inhaled form was based on this surrogate endpoint.

Evidence Gaps and Areas of Scientific Uncertainty

Official literature indicates several areas where research remains limited. For the injectable form, comparative evidence is lacking from modern randomized trials against some of the newest alternatives that were studied for severe systemic infections. Furthermore, a high variability was observed in how the medicine is processed in critically ill populations, indicating that data for certain groups are insufficient for precise estimates of drug levels. For the inhaled form, the clinical benefit (functional status, quality of life) requires further research to be fully established.

Key Studies & References Aminoglycoside Antibiotics Review (NCBI Bookshelf/StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Domak (FAQ)

Q: Is Domak the same type of medicine as [similar drug name]? (high-level)

The active ingredient in Domak (Amikacin) is officially described as a potent medicine belonging to the aminoglycoside antibiotic class. This classification means it functions specifically to disrupt protein creation in susceptible bacteria. Knowing the drug class can help inform general comparisons to other antibiotics that function similarly or differently.

Q: How long does the effect of a dose of Domak last?

The medicine is quickly cleared from the bloodstream, with its serum half-life described as approximately 2.2 hours in adults with normal kidney function. However, its effect on bacteria includes a sustained Post-Antibiotic Effect (PAE), meaning its work continues to suppress bacterial regrowth even after the drug is no longer detectable in the blood.

Q: Does Domak have potential interactions with common over-the-counter pain relievers?

Official regulatory labels state that caution or monitoring may be advised if this medicine is used alongside certain common over-the-counter pain relievers, such as Ibuprofen. Regulatory documents indicate that combining these types of medicines carries a documented risk of additive side effects.

Q: Is Domak ever used for something other than its main approved purpose?

Regulatory documents strictly define Domak’s usage for specific, serious bacterial infections that have been officially reviewed. Use is confined to these official indications, which include serious systemic infections, Multidrug-Resistant Tuberculosis (MDR-TB), and specialized lung infections for the inhalation form.

Q: How is Domak eliminated from the body?

Domak is primarily cleared from the body by the kidneys. Official documentation states that 94%–98% of a single dose is excreted unchanged in the urine within 24 hours. Because the drug relies heavily on kidney function for elimination, monitoring renal status is a mandatory procedural constraint defined in the regulatory labeling.

Q: What is the significance of the research phase Domak went through?

The evidence supporting the use of Domak is based on decades of historical clinical experience and controlled trials. The specialized inhalation formulation underwent controlled Phase 3 Trials, which are the final clinical research step needed for regulatory bodies to assess efficacy and safety endpoints prior to approval.

Q: How quickly should I expect Domak to start working?

The medicine is quickly absorbed into the bloodstream, reaching its peak concentration soon after administration (within 45 minutes to 2 hours). This rapid absorption supports its intended role as a bactericidal medicine for serious infections.

Q: Is Domak a controlled substance?

According to the U.S. Drug Enforcement Administration (DEA) and other regulatory bodies, Domak (Amikacin) is not classified as a controlled substance. However, it remains a prescription-only medicine.

Q: What does the FDA classification of Domak mean?

Official classifications designate Domak as a prescription-only (Rx-only) medicine. For its specialized forms, it was reviewed under pathways such as the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), reflecting its targeted use for serious and refractory infections in specific populations.

Q: Are there any widely known food or drink interactions with Domak?

Regulatory information notes that potential interactions may occur between the medicine and certain foods, as well as with alcohol and tobacco products. The official labeling emphasizes the importance of professional review regarding the use of Domak alongside dietary choices, alcohol, or tobacco.

Q: Are changes in sleep a common experience for people taking Domak?

Official adverse reaction reports list side effects such as drowsiness and lethargy (a feeling of sluggishness) that have been reported by some patients during treatment. These are considered effects on the central nervous system that may influence sleep.

Q: If I miss a dose of Domak, what is the general guidance (non-directive)?

Official guidance documents describe the general procedure for a missed dose as skipping the missed dose and continuing with the next scheduled dose. Regulatory guidance specifies that patients should avoid using a double or extra dose to compensate for the missed administration.

Q: Can Domak affect the results of common laboratory blood tests?

The medicine can cause measurable changes in certain lab markers, particularly those related to kidney function, such as elevated serum creatinine. Regulatory labeling requires the monitoring of these specific lab values, along with urine contents, during the course of therapy.

Q: Does Domak affect the use of hormonal birth control?

In regulatory reviews, Domak has been noted to potentially decrease the level of certain types of oral hormonal birth control. This is due to its documented effect on intestinal flora, though the overall risk of contraceptive failure is generally considered low.

Q: What happens if Domak is stopped suddenly?

Official guidance emphasizes the critical importance of completing the full prescribed course of therapy. The regulatory rationale for this is that finishing the entire course is intended to support the elimination of the target pathogen and reduce the potential for antibiotic resistance.

Q: Is there a generic version of Domak available?

Yes, the active ingredient in Domak, which is amikacin sulfate, is available in generic formulations.

Q: Is Domak known to interact with herbal supplements like St. John's Wort?

Official patient safety information describes the importance of informing healthcare providers about all medicines, vitamins, and herbal products or supplements being taken. This is emphasized in order to ensure a complete interaction review is performed against known constraints.

Q: Is a metallic taste in the mouth a possible side effect of Domak?

Official adverse reaction reports list a change in taste (known as dysgeusia) among the less common side effects reported by some patients using this medicine.

Q: Can Domak cause issues with driving or operating heavy machinery?

Patient safety information warns that this medicine may cause side effects such as dizziness and drowsiness. Official labeling contains warnings stating that driving or performing complex activities should be avoided until an individual knows how the medicine affects their personal alertness and coordination.

Q: Is it normal to feel a change in appetite while taking Domak?

Official adverse event reports indicate that some patients taking the medicine have reported a decreased appetite (anorexia) as a possible side effect.

Q: Does Domak have a risk of causing weight changes?

Regulatory safety documents list both decreased weight (weight loss) and rapid weight gain among the side effects reported by some patients using this medicine.

Q: Can Domak be safely taken by someone with a history of alcohol use?

Regulatory guidance documents describe the importance of professional review regarding the use of this medicine alongside alcohol and tobacco. This is due to documentation noting that potential interactions may occur.

Q: Does Domak have any known effects on mood or mental clarity?

Official adverse reaction reports list effects related to mental state and clarity, including confusion, agitation, anxiety, and depression, among the less frequent side effects reported by patients.

How should Domak be stored and disposed of?

How to Store and Dispose of Domak?

The storage and disposal of Domak (Amikacin) must strictly follow the official instructions found in the regulatory labeling.

Storage Requirements

Domak must be stored at Controlled Room Temperature, typically 25 C (77 F), and protected from both freezing and excessive heat. The medicine must be kept in its original container to shield it from direct sunlight and moisture. Vials are for single use only; any solution that has been diluted or opened must be used immediately, and any unused portion must be discarded, not stored for later use.

Safety and Disposal

It is mandatory to Keep this medicine out of the sight and reach of children. When disposing of the product, do not throw away Domak via wastewater or household waste. Disposal must be done according to all local pharmaceutical waste regulations by returning it to a pharmacist or designated collection system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Domak found in:

A-Z Index: